Treatment Approach for Triglycerides 151 mg/dL and LDL 101 mg/dL
Start with intensive therapeutic lifestyle changes as first-line therapy, and consider statin therapy if the patient has additional cardiovascular risk factors or diabetes. 1
Risk Stratification First
Your immediate next step is to calculate this patient's 10-year ASCVD risk using the pooled cohort equations and assess for:
- Diabetes mellitus
- Known cardiovascular disease
- Chronic kidney disease
- Family history of premature CAD
- Metabolic syndrome components (waist circumference, blood pressure, HDL-C, fasting glucose)
The patient's lipid values place them in a borderline category where treatment intensity depends entirely on overall cardiovascular risk 2.
Therapeutic Lifestyle Changes (Mandatory for All Patients)
Implement these interventions immediately—they can reduce triglycerides by 50% or more when combined: 3
Diet Modifications
- Reduce saturated fat to <7% of total calories and cholesterol to <200 mg/day 4
- Eliminate trans fats completely
- Reduce refined carbohydrates and added sugars (can lower TG by 10-20%) 3
- Limit fructose intake
- Add viscous/soluble fiber 10-25 g/day 2, 5
- Consider plant stanols/sterols 2 g/day 4
- Increase omega-3 fatty acids from fish or consider 1 g/day supplementation 4
Weight and Physical Activity
- Target 5-10% weight reduction (anticipates 20% TG reduction) 3
- 30-60 minutes moderate-intensity aerobic activity most days, preferably daily 4, 6
- Resistance training 2 days per week 2
Alcohol
Pharmacotherapy Decision Algorithm
If Patient Has High ASCVD Risk (≥7.5% 10-year risk) OR Diabetes OR Known CVD:
Initiate statin therapy immediately 1, 7
- LDL-C goal: <100 mg/dL (patient is currently at 101 mg/dL) 4
- For very high-risk patients (established CVD), further reduction to <70 mg/dL is reasonable 4, 6
- Moderate-to-high intensity statin is appropriate given the borderline LDL elevation
If triglycerides remain ≥150 mg/dL after maximally tolerated statin AND patient has:
- Established ASCVD OR
- Diabetes with ≥2 additional CV risk factors
Then consider adding icosapent ethyl (purified EPA) for additional cardiovascular risk reduction 8, 7, 9. This is the only triglyceride-lowering therapy proven to reduce cardiovascular events beyond statin therapy.
If Patient Has Borderline Risk (5-7.4% 10-year risk):
Statin therapy can be considered 9
- Emphasize lifestyle modifications first
- Reassess in 3 months
- If TG remains ≥150 mg/dL or LDL-C remains >100 mg/dL after lifestyle changes, initiate statin
If Patient Has Low Risk (<5% 10-year risk) and 0-1 Risk Factors:
Continue intensive lifestyle modifications alone 2, 10
- Recheck fasting lipid panel in 3 months
- Consider statin only if LDL-C rises to ≥190 mg/dL 2
Secondary Causes to Evaluate
Rule out and treat these conditions that elevate triglycerides 1, 11:
- Uncontrolled diabetes (check HbA1c)
- Hypothyroidism (check TSH)
- Chronic kidney disease (check creatinine, urinalysis)
- Nephrotic syndrome
- Chronic liver disease (check LFTs)
- Medications: thiazides, beta-blockers, oral estrogens, tamoxifen, glucocorticoids, atypical antipsychotics, protease inhibitors, bile acid sequestrants
Important Caveats
The 2019 ACC/AHA guideline 1 represents the most current evidence and emphasizes that triglycerides 150-499 mg/dL warrant lifestyle intervention as the foundation, with statin therapy based on overall ASCVD risk rather than the triglyceride level itself.
Fibrates and niacin are NOT recommended for cardiovascular risk reduction in combination with statins—the FDA withdrew approval for this indication in 2016 due to unfavorable benefit-risk profiles 11. They should be reserved only for severe hypertriglyceridemia (≥500 mg/dL) to prevent pancreatitis 1, 3.
Non-HDL cholesterol is a useful secondary target when triglycerides are elevated. Calculate it as: Total cholesterol - HDL-C. Goal is <130 mg/dL for most patients 4.
Do not use combination EPA/DHA fish oils for cardiovascular risk reduction—only purified icosapent ethyl has proven benefit 8, 7.